Lung surfactant therapy is a standard, safe and effective therapy for the treatment of ARDS in neonates, however clinical trials on recombinant SP-C based surfactant was found to be ineffective in the treatment of ARDS in adults (Spragg et al., 2004). This evidence concerns the gene SFTPC and acute respiratory distress syndrome.